Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Antibody Discovery Services
Overview
Target Analysis & Immunization
Antibody Discovery & Characterization
Developability Profiling
Optimization & Engineering
Preclinical Services
Protein Production
Overview
 
Online Store

Explore now

See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
AI Technology
LENSai Applications
The LENSai Difference
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Resources
Antibody Discovery Resources
AI Technology Resources
IPA Collective
Resource Spotlight
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Company
Overview
Leadership
Investor Relations
Careers
Locations
Contact Us
News
News & Press Releases
Events
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

In the News

Contact Us

IPA News
July 3rd, 2025
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
New benchmark confirms LENSai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise...
June 24th, 2025
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant...
June 12th, 2025
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug...
June 5th, 2025
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a...
May 12th, 2025
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping...
April 11th, 2025
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration’s (FDA) recent decision to phase out animal testing requirements...
March 13th, 2025
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics
Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas - ImmunoPrecise Antibodies Ltd....
February 26th, 2025
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering...
February 24th, 2025
ImmunoPrecise Antibodies Announces Key Leadership Changes
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev...
June 12th, 2024
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
VICTORIA, British Columbia, June 12, 2024 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand,...
November 27th, 2023
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
VICTORIA, British Columbia, November 27, 2023 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board of Director...
November 13th, 2023
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary,...